Cue biopharma provides update on most advanced clinical stage asset, cue-101, presented by dr. dimitrios colevas at the dava 4th hawaii global summit on thoracic malignancies

Orr of 50% in treatment-naÏve patients with hpv+ r/m hnscc 12-month landmark survival of 88% and mos of 32 months
CUE Ratings Summary
CUE Quant Ranking